TY - JOUR
T1 - Antiplatelet therapy in the elderly
T2 - Aspirin, ticlopidine-clopidogrel, and GPIIb/GPIIIa antagonists
AU - Calverley, David C.
PY - 2001
Y1 - 2001
N2 - Antiplatelet agents including aspirin, dipyridamole, the thienopyridines, and the GPIIb/IIla antagonists have collectively demonstrated their ability to have a significant impact on the incidence of recurrent MIs, strokes, and other vascular ischemic events in the geriatric population. Low-dose aspirin also seems to be effective and safe for the primary prevention of ischemic heart disease in men considered at high risk. There is no evidence that the recommendations from these studies had increased relevance to younger adults, and the studies considering age as a variable found antiplatelet agents had either similar or increased benefit in older patients. In view of the relatively reduced adverse effects of these agents when compared with their potential therapeutic benefit, it is important that they be considered in all older patients for secondary prevention and in certain high-risk groups for primary prevention of cardiovascular morbidity and mortality.
AB - Antiplatelet agents including aspirin, dipyridamole, the thienopyridines, and the GPIIb/IIla antagonists have collectively demonstrated their ability to have a significant impact on the incidence of recurrent MIs, strokes, and other vascular ischemic events in the geriatric population. Low-dose aspirin also seems to be effective and safe for the primary prevention of ischemic heart disease in men considered at high risk. There is no evidence that the recommendations from these studies had increased relevance to younger adults, and the studies considering age as a variable found antiplatelet agents had either similar or increased benefit in older patients. In view of the relatively reduced adverse effects of these agents when compared with their potential therapeutic benefit, it is important that they be considered in all older patients for secondary prevention and in certain high-risk groups for primary prevention of cardiovascular morbidity and mortality.
UR - http://www.scopus.com/inward/record.url?scp=0035116232&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035116232&partnerID=8YFLogxK
U2 - 10.1016/S0749-0690(05)70104-X
DO - 10.1016/S0749-0690(05)70104-X
M3 - Article
C2 - 11270132
AN - SCOPUS:0035116232
SN - 0749-0690
VL - 17
SP - 31
EP - 48
JO - Clinics in Geriatric Medicine
JF - Clinics in Geriatric Medicine
IS - 1
ER -